hero image

Biogen Announces Webcast of Annual Meeting of Stockholders

May 25, 2021 Investor Relations

Cambridge, Mass. – Biogen Inc. (Nasdaq: BIIB) announced today that the webcast of the Company's 2021 Annual Meeting of Stockholders will be held on Wednesday, June 2, 2021 at 9:00 a.m. Eastern Time. A live audio webcast of the meeting will be available on the Investor Relations section of the Company's corporate website at www.biogen.com/investors or directly via www.virtualshareholdermeeting.com/BIIB2021.  An archive of the webcast will be available for replay following the meeting.  Please allow at least 10 minutes prior to the event to visit the site and download the necessary software to listen to the webcast. 

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.


Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442

thumb
December 1, 2021
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total Zuranolone 50 mg was generally well-tolerated with an overall adverse

thumb
November 17, 2021
Update on Regulatory Review of Aducanumab in the European Union

CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimer’s